Fensolvi FDA Approval History
FDA Approved: Yes (First approved May 1, 2020)
Brand name: Fensolvi
Generic name: leuprolide acetate
Dosage form: Injection
Company: Tolmar Pharmaceuticals, Inc.
Treatment for: Precocious Puberty
Fensolvi (leuprolide acetate) is a gonadotropin releasing hormone (GnRH) agonist indicated for the treatment of pediatric patients 2 years of age and older with central precocious puberty.
Development Timeline for Fensolvi
|May 5, 2020||Approval FDA Approves Fensolvi (leuprolide acetate) for Injectable Suspension for Pediatric Patients with Central Precocious Puberty|
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.